ATE283286T1 - Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion - Google Patents
Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktionInfo
- Publication number
- ATE283286T1 ATE283286T1 AT01941783T AT01941783T ATE283286T1 AT E283286 T1 ATE283286 T1 AT E283286T1 AT 01941783 T AT01941783 T AT 01941783T AT 01941783 T AT01941783 T AT 01941783T AT E283286 T1 ATE283286 T1 AT E283286T1
- Authority
- AT
- Austria
- Prior art keywords
- adnf
- blends
- memory function
- improve learning
- learning
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20894400P | 2000-05-31 | 2000-05-31 | |
US26780501P | 2001-02-08 | 2001-02-08 | |
PCT/US2001/017758 WO2001092333A2 (en) | 2000-05-31 | 2001-05-31 | Use of adnf for enhancing learning and memory |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE283286T1 true ATE283286T1 (de) | 2004-12-15 |
Family
ID=26903662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01941783T ATE283286T1 (de) | 2000-05-31 | 2001-05-31 | Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion |
Country Status (12)
Country | Link |
---|---|
US (2) | US7427598B2 (de) |
EP (1) | EP1285000B1 (de) |
JP (1) | JP4440536B2 (de) |
CN (1) | CN1444600A (de) |
AT (1) | ATE283286T1 (de) |
AU (2) | AU2001275111B2 (de) |
CA (1) | CA2410735A1 (de) |
DE (1) | DE60107416T2 (de) |
HK (1) | HK1054947A1 (de) |
MX (1) | MXPA02011923A (de) |
NZ (1) | NZ522821A (de) |
WO (1) | WO2001092333A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
US7384908B1 (en) | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
US7427598B2 (en) * | 2000-05-31 | 2008-09-23 | The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory |
AU2002335750A1 (en) * | 2001-09-12 | 2003-03-24 | Ramot At Tel-Aviv University Ltd. | Neurotrophic components of the adnf i complex |
JP5036302B2 (ja) * | 2003-02-10 | 2012-09-26 | ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ | 炎症状態下に血液脳関門で示差的(differentially)に発現される核酸 |
WO2004080957A2 (en) | 2003-03-12 | 2004-09-23 | Ramot At Tel Aviv University Ltd. | Use of adnf polypeptides for treating anxiety and depression |
WO2005099741A1 (ja) | 2004-04-08 | 2005-10-27 | Noevir Co., Ltd. | 運動ニューロン疾患治療薬 |
EP1885389A4 (de) | 2005-03-23 | 2012-04-04 | Univ Ramot | Verwendung von adnf-polypeptiden zur behandlung von peripherer neurotoxizität |
TWI303567B (en) * | 2005-12-20 | 2008-12-01 | Ind Tech Res Inst | Oligopeptide, derivative thereof, and pharmaceutical composition comprising the same |
US20070185035A1 (en) * | 2005-12-23 | 2007-08-09 | Nastech Pharmaceutical Company Inc. | Enhanced mucosal administration of neuroprotective peptides |
WO2007096859A2 (en) * | 2006-02-24 | 2007-08-30 | Ramot At Tel-Aviv University Ltd. | Protection of the retina against laser injury by adnf peptides such as nap and sal |
KR20100063719A (ko) * | 2007-08-24 | 2010-06-11 | 라모트 앳 텔-아비브 유니버시티 리미티드 | Nap 유사 및 sal 유사 펩티드 모의체를 사용한 신경보호 |
WO2011021186A1 (en) | 2009-08-17 | 2011-02-24 | Ramot At Tel-Aviv University, Ltd. | Nap alpha-aminoisobutyric acid analog with neuroprotective activity |
WO2011083461A2 (en) | 2010-01-06 | 2011-07-14 | Ramot At Tel-Aviv University, Ltd. | Method for diagnosing and monitoring schizophrenia and tauopathies |
WO2012015910A2 (en) * | 2010-07-28 | 2012-02-02 | Allon Therapeutics Inc. | Use of adnf polypeptides for treating neurodegenerative diseases |
US20190192629A1 (en) * | 2015-11-18 | 2019-06-27 | Herantis Pharma Plc | Compositions Comprising CDNF or MANF for use in the Intranasal Treatment of Central Nervous System Diseases |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4587046A (en) * | 1982-05-18 | 1986-05-06 | The Regents Of The University Of California | Drug-carrier conjugates |
DE69233492D1 (de) * | 1991-04-22 | 2005-04-28 | Nasa | Aktivitätsabhängiger neurotropher faktor |
US6174862B1 (en) * | 1991-04-22 | 2001-01-16 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Neurotrophic peptides of activity dependent neurotrophic factor |
US6310040B1 (en) * | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
AU4238493A (en) * | 1992-05-08 | 1993-12-13 | Thomas Jefferson University | IGF-1 analogs |
AU737406B2 (en) | 1997-02-07 | 2001-08-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Activity dependent neurotrophic factor III (ADNF III) |
US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
US6933277B2 (en) * | 1999-03-12 | 2005-08-23 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides |
US7384908B1 (en) * | 1999-08-18 | 2008-06-10 | National Institute Of Health | Orally active peptides that prevent cell damage and death |
CA2381981A1 (en) | 1999-08-18 | 2001-02-22 | Douglas E. Brenneman | Orally active peptides that prevent cell damage and death |
US7427598B2 (en) * | 2000-05-31 | 2008-09-23 | The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory |
-
2001
- 2001-05-31 US US10/296,849 patent/US7427598B2/en not_active Expired - Fee Related
- 2001-05-31 AT AT01941783T patent/ATE283286T1/de not_active IP Right Cessation
- 2001-05-31 CN CN01810354A patent/CN1444600A/zh active Pending
- 2001-05-31 AU AU2001275111A patent/AU2001275111B2/en not_active Ceased
- 2001-05-31 DE DE60107416T patent/DE60107416T2/de not_active Expired - Lifetime
- 2001-05-31 AU AU7511101A patent/AU7511101A/xx active Pending
- 2001-05-31 JP JP2002500944A patent/JP4440536B2/ja not_active Expired - Fee Related
- 2001-05-31 WO PCT/US2001/017758 patent/WO2001092333A2/en active IP Right Grant
- 2001-05-31 EP EP01941783A patent/EP1285000B1/de not_active Expired - Lifetime
- 2001-05-31 MX MXPA02011923A patent/MXPA02011923A/es active IP Right Grant
- 2001-05-31 CA CA002410735A patent/CA2410735A1/en not_active Abandoned
- 2001-05-31 NZ NZ52282101A patent/NZ522821A/en not_active IP Right Cessation
-
2003
- 2003-08-22 HK HK03106025A patent/HK1054947A1/xx not_active IP Right Cessation
-
2008
- 2008-08-25 US US12/197,986 patent/US20090203615A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60107416D1 (de) | 2004-12-30 |
US20040048801A1 (en) | 2004-03-11 |
JP4440536B2 (ja) | 2010-03-24 |
NZ522821A (en) | 2004-08-27 |
WO2001092333A2 (en) | 2001-12-06 |
US7427598B2 (en) | 2008-09-23 |
AU7511101A (en) | 2001-12-11 |
HK1054947A1 (en) | 2003-12-19 |
MXPA02011923A (es) | 2004-09-06 |
CA2410735A1 (en) | 2001-12-06 |
WO2001092333A3 (en) | 2002-05-30 |
EP1285000B1 (de) | 2004-11-24 |
EP1285000A2 (de) | 2003-02-26 |
JP2003535105A (ja) | 2003-11-25 |
AU2001275111B2 (en) | 2006-07-06 |
DE60107416T2 (de) | 2005-12-01 |
US20090203615A1 (en) | 2009-08-13 |
CN1444600A (zh) | 2003-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60107416D1 (de) | Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion | |
DE602005016800D1 (de) | Hif-prolylhydroxylase-aktivitätstest | |
DE60019458D1 (de) | Stabilisierendes verdünnungsmittel für polypeptide und antigene | |
AU4185001A (en) | Protein scaffolds for antibody mimics and other binding proteins | |
WO2003104418A3 (en) | RECONSTITUTED POLYPEPTIDES | |
DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
DE69829293D1 (de) | Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen | |
DE69942459D1 (de) | Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung | |
DE59903410D1 (de) | Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung | |
NO20030548D0 (no) | Substratbehandling for rustfritt stål | |
DE69739375D1 (de) | Verfahren zur regulierung der stickstoffmonoxid-erzeugung | |
ATE347611T1 (de) | Automatischer apparat zum messen von wassertoxizität | |
YU18903A (sh) | Fuzioni proteini od inhibitora protivtela citokin- citokin (selektokin) kao ciljno specifični pro-lek | |
ATE365801T1 (de) | Modulierung durch il-tif/interleukin-21 | |
WO2005016233A3 (en) | Botulinum neurotoxin b receptors and use thereof | |
ATE274190T1 (de) | Methoden und kits zum sequenzieren von polypeptiden | |
DK1540335T3 (da) | Screeningsfremgangsmåder til kognitive forstækere | |
ATE555126T1 (de) | Relaxin-chimere polypeptide und deren herstellung und anwendung | |
TW200727909A (en) | Enterokinesis promoting ingesta | |
ATE476447T1 (de) | Verfahren und zusammensetzungen zur modulation und zum nachweis von wisp-aktivität | |
WO2006084189A3 (en) | Method for determining thermal stability of collagen or collagen-like peptide | |
ATE319090T1 (de) | Verwendung eines papillarfibroblast-spezifischen antikörpers als marker der hautqualität | |
ATE339683T1 (de) | Verfahren zur detektion und konzentrationsbestimmung von schwefelfreien odoriermitteln in erd- oder brenngas | |
WO2003053855A3 (en) | Rapid high-throughput screen for detecting biological species in ballast water | |
WO2005060998A3 (en) | Methods of modulating cytokine activity; related reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |